Jefferson Medical College BostonGene, Thomas Jefferson University Partner on Head, Neck Cancer Research The partners will apply whole-exome and whole-transcriptome analysis to evaluate two existing drugs for squamous cell carcinoma treatment. Taproot Health, Five Cancer Centers Agree to Conduct Precision Oncology Master Trial, Share Data Within the master observational trial, the organizations have agreed to prospectively collect real world data and ultimately build a national oncology database. Jefferson Medical Wins $3M MicroRNA Grant The research will involve a partnership with Baylor that will focus on microRNA influences on platelet function in the blood. People in the News: Mar 10, 2009 Premium Al Luderer, Kevin Krenitsky Breaking News Plasmid Transfer Let Cholera Pathogen in Yemen Become Multidrug Resistant, Study Suggests Harbinger Health Raises $140 Million in Series B Financing BioMérieux's BioFire Defense Secures $18.8M US DoD Contract for Infectious Disease Testing Biora Therapeutics Settles Claims of Misleading Genetic Testing Advertisements Genetic Overlap Between Schizophrenia, Cardiovascular Disease Risk Uncovered by GWAS Analysis The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.